Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment. NICE technology appraisal guidance 1001

National Institute for Health and Care Excellence (NICE)
Record ID 32018013322
English
Details
Project Status: Completed
Year Published: 2024
URL for published report: https://www.nice.org.uk/guidance/ta1001
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England
MeSH Terms
  • Lymphoma
  • Lymphoma, B-Cell, Marginal Zone
  • Antineoplastic Agents
  • Hematologic Agents
  • Tyrosine Kinase Inhibitors
Contact
Organisation Name: National Institute for Health and Care Excellence
Contact Address: Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.